(Q39719978)

English

TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.

scientific article published on 9 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

0 references

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Lise Eckhoff

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Mette Nielsen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Susanne Moeller

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

9 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Acta Oncologica

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

50

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1075-1082

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824038%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Economic evaluation of docetaxel for breast cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.602111

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39719978&oldid=2089130304"